{
    "clinical_study": {
        "@rank": "84025", 
        "arm_group": [
            {
                "arm_group_label": "Tribulus Terrestris", 
                "arm_group_type": "Experimental", 
                "description": "patients will use Tribulus terrestris (750 mg/day) during 120 days"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "patients will use placebo for 120 days"
            }
        ], 
        "brief_summary": {
            "textblock": "Hypoactive Sexual Desire Disorder ( HSDD ) is very common in postmenopausal women due to a\n      reduction in circulating androgen levels. The aim of this study is to evaluate the effects\n      of Tribulus Terrestris in premenopausal women with HSDD."
        }, 
        "brief_title": "Effects of Tribulus Terrestris in Postmenopausal Women With Hypoactive Sexual Desire Disorder", 
        "completion_date": {
            "#text": "August 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Menopause", 
            "Sexual Abstinence"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Sexual Dysfunctions, Psychological", 
                "Hypokinesia"
            ]
        }, 
        "detailed_description": {
            "textblock": "Hypoactive Sexual Desire Disorder ( HSDD ) is the most prevalent female sexual dysfunction\n      in society mainly in postmenopausal women, and is strongly linked to the quality of life of\n      women . The androgen hormones decline over age in the premenopausal period, more sharply\n      after menopause. Tribulus terrestris is a plant native to India , recommended in the\n      treatment of infertility , low libido and impotence . Its main active ingredient is the\n      protodioscin , which has been attributed to an increase in testosterone levels and improved\n      sexual function . The aim of this study is to evaluate the effects of Tribulus Terrestris in\n      premenopausal women with HSDD ."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  at least one year after last menstrual period\n\n          -  with no use of hormonal replacement therapy within the last 3 months\n\n          -  without any medication, drugs or alcohol.\n\n          -  Healthy patients without systemic or psychiatric disease\n\n        Exclusion Criteria:\n\n          -  Patient smoker (10 cigarettes per day).\n\n          -  Patients with blood pressure > 160/90 mm Hg.\n\n          -  Patient with breast or endometrial carcinoma.\n\n          -  Patients with a history of myocardial infarction.\n\n          -  Patient with Diabetes.\n\n          -  Patient with vaginal bleeding from any source.\n\n          -  Patients with hepatic injury.\n\n          -  Patients with active thrombophlebitis or thromboembolic disorders recent\n\n          -  Patients with interpersonal relationship problems with your relationship or partner\n\n          -  Patients with sexual problems from your partner"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "50 Years"
        }, 
        "enrollment": {
            "#text": "44", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 29, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01975649", 
            "org_study_id": "TTC", 
            "secondary_id": "245.553C"
        }, 
        "intervention": [
            {
                "arm_group_label": "Tribulus Terrestris", 
                "description": "patients will use 750 mg/day during 120 days", 
                "intervention_name": "Tribulus Terrestris", 
                "intervention_type": "Drug", 
                "other_name": "tribulus"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "patients will use placebo pills with the same shape of the drug", 
                "intervention_name": "Placebo", 
                "intervention_type": "Other"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "postmenopausal", 
            "hypoactive", 
            "sexual disorder", 
            "androgen"
        ], 
        "lastchanged_date": "October 29, 2013", 
        "location": {
            "contact": {
                "email": "sjgeber@terra.com.br", 
                "last_name": "Selmo Geber, MD PhD", 
                "phone": "55 31 34099304"
            }, 
            "contact_backup": {
                "email": "karlazanolla.souza@gmail.com", 
                "last_name": "Karla Zanolla, MD", 
                "phone": "55 (31) 9923-2737"
            }, 
            "facility": {
                "address": {
                    "city": "Belo Horizonte", 
                    "country": "Brazil", 
                    "state": "Minas Gerais", 
                    "zip": "30130100"
                }, 
                "name": "Hospital das Clinicas - Universidade Federal de Minas Gerais"
            }, 
            "investigator": {
                "last_name": "Selmo Geber, MD PhD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Brazil"
        }, 
        "number_of_arms": "2", 
        "official_title": "Effects of Tribulus Terrestris in Postmenopausal Women With Hypoactive Sexual Desire Disorder", 
        "other_outcome": {
            "description": "Blood test", 
            "measure": "serum levels of testosterone and sex hormone-binding globulin (SHBG)", 
            "safety_issue": "No", 
            "time_frame": "120 days"
        }, 
        "overall_contact": {
            "email": "sjgeber@terra.com.br", 
            "last_name": "Selmo Geber, MD PhD", 
            "phone": "55 31 34099304"
        }, 
        "overall_contact_backup": {
            "email": "karlazanolla.souza@gmail.com", 
            "last_name": "Karla Zanolla, MD", 
            "phone": "55 (31) 9923-2737"
        }, 
        "overall_official": {
            "affiliation": "Federal University of Minas Gerais", 
            "last_name": "Selmo Geber, MD PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Brazil: National Committee of Ethics in Research", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "August 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "we will use the \"Quotient Sexual - Version Feminine (QS-F) brazilian questionary to make the evaluation", 
            "measure": "Sexual Desire", 
            "safety_issue": "No", 
            "time_frame": "120 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01975649"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Federal University of Minas Gerais", 
            "investigator_full_name": "Selmo Geber", 
            "investigator_title": "MD, PhD", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "Blood test", 
            "measure": "serum levels of prolactin and thyroid-stimulating hormone (TSH)", 
            "safety_issue": "No", 
            "time_frame": "120 days"
        }, 
        "source": "Federal University of Minas Gerais", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Federal University of Minas Gerais", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2013"
    }
}